A second class of IL2-based therapeutics biases the cytokine towards IL2Rα binding; NKTR-358 uses permanent PEG conjugation to selectively induce Treg proliferation without expanding CD8+ and CD4+ T-cells and is undergoing multiple Phase 1 trials for treatment of autoimmune disorders [286]. Here, IL2 is linked to autoimmune disease.